New warnings for anemia drugs
From Times Wire Services
Drug maker Amgen Inc. said regulators had added new warnings about the risks of death and tumor growth to the Thousand Oaks company’s blockbuster anemia drugs.
The warnings approved by the Food and Drug Administration say that Aranesp and Epogen increased the likelihood of death and accelerated tumor growth in patients with several types of cancer, including breast and cervical. The warnings also apply to Johnson & Johnson’s drug Procrit.
